Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (29627)	12/14/1999 10:21:00 AM
From: Robert Cohen	Read Replies (1) \| Respond to of 32384

Targretin article due out tomorrow. Not sure we can stand any more good news. Robert

To: bob zagorin who wrote (29627)	12/14/1999 10:34:00 AM
From: RWReeves	Respond to of 32384

Everyone expected approval, now that it's in hand, market's instinct is to sell LGND. CBS et al make a living by feeding people what hey think they want to hear; Another CLTR, another LIPO. So there's no rush of new investors in to LGND. The shorts are the ones to watch: once they rush in there should be a buying opportunity. Best to hold this, co. was worth less before rather than after approval. LGND has market access now, off label use will be substantial, US approval gives LGND "free sale" that gets it into a lot of other countries that watch and follow FDA's action. Legg Mason is dumber than a bunch of rocks. LT LGND investors should not be. RWR